Citi ups Australia's Healius to 'neutral' rating, sees special dividend on the cards

Healius

19/11/2024 20:14

** Citi upgrades Healius'  HLS.AX  rating to "neutral" from
"sell" on recent share price decline, the sale of co's unit
Lumus Imaging and cost base of its pathology segment reflecting
its true business as usual costs
    ** Brokerage trims price target for co to A$1.05 from A$1.5
to reflect Lumus sale in its forecasts
    ** Citi forecasts HLS to distribute special dividend of 40
Australian cents/share from sale of Lumus
    ** The Aussie healthcare firm on Friday shared positive
outlook for its pathology business, foreacsting strong growth in
2H
    ** HLS down ~19.9% YTD as of last close, underperforming
against a 3.4% gain on the ASX Health Care index  .AXHJ 

($1 = 1.5319 Australian dollars)

 (Reporting by Nikita Maria Jino in Bengaluru)
 ((Nikita.Jino@thomsonreuters.com))